MDM2 and neoplasm: The HDM201 compound developed by Novartis is an imidazopyrrolidinone scaffold-based inhibitor of MDM2 which showed a significant anti-tumor activity in vitro and more efficient and better pharmacokinetic and pharmacodynamic profiles in in vivo models [104].